[논문]Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

doi:10.1016/j.clml.2014.09.008

Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Clinical lymphoma, myeloma & leukemia, v.15 no.4, 2015년, pp.199 - 207

Abstract ▼ AI-Helper

This systematic literature review with meta-analysis was conducted on the clinical efficacy and safety of interventions used in the treatment of chronic lymphocytic leukemia (CLL). We systematically searched databases (PubMed, Cochrane Library, and Embase; 1997 to August 2, 2012), conference abstracts, bibliographic reference lists, recent reviews, and Clinicaltrials.gov. Primary efficacy outcomes were objective response rate, progression-free survival, and overall survival. Safety end points were Grade ¾ toxicities, serious adverse events, withdrawals because of toxicity, and deaths due to toxicity. Studies were selected if they were randomized controlled trials (RCTs) reporting on the efficacy or safety of relapsed or refractory CLL and if outcomes for CLL were reported separately from trials that included other lymphoid neoplasms. We used the Bucher method for conducting adjusted indirect comparisons within a meta-analysis. We identified 6 RCTs of pharmacologic treatment for relapsed/refractory CLL. The most common drugs investigated (alone or in combination) were fludarabine and cyclophosphamide. When reported, median overall survival ranged from 27.3 to 52.9 months, and overall response rate from 58% to 82%. Although meta-analysis of efficacy results was considered, details are not presented because only 3 studies qualified and the common comparator treatment was not clinically relevant. The relatively small number of RCTs, few overlapping treatment arms, and variability in end points studied make it difficult to formally compare therapies for relapsed/refractory CLL. Significant variability in RCT features presents a further challenge to meaningful comparisons. Additional well-designed RCTs are needed to fully understand the relative efficacy and safety of older and more recently developed therapies.

참고문헌 (32)

National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Statistics Review: 1975-2010. Available at: http://seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_13_leukemia.pdf. Accessed November 21, 2013.
American Cancer Society. What are the key statistics for chronic lymphocytic leukemia? Available at: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf. Accessed May 14, 2014.
J Clin Oncol Harris 17 3835 1999 10.1200/JCO.1999.17.12.3835 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997

상세보기
Cancer Manag Res Chao 5 251 2013 10.2147/CMAR.S34273 Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies

상세보기
N Engl J Med Rai 343 1750 2000 10.1056/NEJM200012143432402 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

상세보기
Expert Rev Anticancer Ther Molica 11 1333 2011 10.1586/era.11.118 Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial

상세보기
NICE. National Institute for Health and Care Excellence. Specification for manufacturer/sponsor submission of evidence. Available at: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf. Accessed March 20, 2013.
Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Available at: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed March 20, 2013.
J Clin Epidemiol Bucher 50 683 1997 10.1016/S0895-4356(97)00049-8 The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

상세보기
Br J Haematol Robak 108 357 2000 10.1046/j.1365-2141.2000.01850.x Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

상세보기
Haematologica Robak 90 994 2005 The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil

상세보기
Clinicaltrials.gov [Web site]. Efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL). Available at: http://clinicaltrials.gov/ct2/show/NCT00802737?term=NCT00802737&rank=1. Accessed July 17, 2013.
J Clin Oncol O'Brien 25 1114 2007 10.1200/JCO.2006.07.1191 Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

상세보기
Lancet Oncol Elter 12 1204 2011 10.1016/S1470-2045(11)70242-X Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

상세보기
Cancer Faderl 107 916 2006 10.1002/cncr.22097 Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

상세보기
Br J Haematol Hillmen 152 570 2011 10.1111/j.1365-2141.2010.08317.x A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

상세보기
J Clin Oncol O'Brien 27 5208 2009 10.1200/JCO.2009.22.5748 Five-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

상세보기
J Clin Oncol Robak 28 1756 2010 10.1200/JCO.2009.26.4556 Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

상세보기
10.1182/blood.V118.21.2859.2859 Wendtner C, Fraser G, Goldberg S, et al. Interim results for the safety and efficacy of different lenalidomide starting dose regimens in subjects with relapsed or refractory chronic lymphocytic leukemia (CC-5013-CLL-009 Study). Presented at the 2011 ASH annual meeting; December 11, 2011. San Diego, CA.

상세보기
Blood Cheson 87 4990 1996 10.1182/blood.V87.12.4990.bloodjournal87124990 National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

상세보기
FDA. US Food and Drug Administration. FDA News Release: FDA approves Imbruvica to treat chronic lymphocytic leukemia. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm385764.htm. Accessed May 16, 2014.
Gilead Sciences. US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin's Lymphoma. Available at: http://www.gilead.com/news/press-releases/2014/1/us-fda-accepts-new-drug-application-for-gileads-idelalisib-for-the-treatment-of-refractory-indolent-nonhodgkins-lymphoma. Accessed May 16, 2014.
Ann Oncol Eichhorst 22 suppl 6 vi50 2011 10.1093/annonc/mdr377 Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

상세보기
J Clin Oncol Fischer 29 3559 2011 10.1200/JCO.2010.33.8061 Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

상세보기
10.1200/jco.2013.31.15_suppl.7003 Brown JR, Furman RR, Flinn I, et al. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.

상세보기
10.1200/jco.2013.31.15_suppl.tps8614 Salles GA, Gopal AK, Martin P, et al. An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. Presented at the Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.

상세보기
10.1200/jco.2013.31.15_suppl.tps8619 Byrd JC, Barrientos JC, Devereux S, et al. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.

상세보기
J Clin Oncol Byrd 32 5s 2014 10.1200/jco.2014.32.15_suppl.lba7008 Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase III RESONATE trial

상세보기
10.1182/blood.V122.21.871.871 Flynn JM, Andritsos LA, Jones JA, et al. Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Presented at the 55th ASH Annual Meeting and Exposition, December 4-10, 2013. New Orleans, LA.

상세보기
J Clin Oncol Gladstone 32 2014 10.1200/jco.2014.32.15_suppl.3028 Phase 2 open-lable study of MEDI-551 and bendamustine versus rituximab and bendamusting in adults with relapsed or refractory CLL

상세보기
J Clin Oncol Sharman 32 5s 2014 10.1200/jco.2014.32.15_suppl.7007 Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia

상세보기
J Clin Oncol Seymour 32 5s 2014 10.1200/jco.2014.32.15_suppl.7015 ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic keukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Abstract ▼ AI-Helper

참고문헌 (32)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트